Clinical Trial Update: A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification [Phase 3]

View source ↗

Summary

Phase 3 trial of ABT-414 in newly diagnosed glioblastoma with EGFR amplification completed; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• ABT-414 (depatuxizumab mafodotin)

Snippet

Sponsor: AbbVie | Conditions: Glioblastoma, Gliosarcoma | Phase 3 | Status: COMPLETED | Results posted: 2023-05-11